Indian Journal of Urology Users online:3444  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2023  |  Volume : 39  |  Issue : 2  |  Page : 148-155

Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India


1 Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
2 Department of Community Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Radiation Oncology, Homi Bhabha Cancer Hospital, Tata Memorial Centre, Sangrur, Punjab, India
4 Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai, Maharashtra, India
5 Department of Medical Oncology, Homi Bhabha Cancer Hospital, Tata Memorial Centre, Sangrur, Punjab, India
6 Department of Pathology, Homi Bhabha Cancer Hospital, Tata Memorial Centre, Sangrur, Punjab, India
7 Homi Bhabha Cancer Hospital, Tata Memorial Centre, Sangrur, Punjab, India
8 Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Training School Complex, Mumbai, Maharashtra, India

Correspondence Address:
Atul Madhukar Budukh
Centre for Cancer Epidemiology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/iju.iju_38_23

Rights and Permissions

Introduction: There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India. Methods: In the year 2013–2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method. Results: Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10–0.27]). Conclusion: To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1574    
    Printed12    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal

 

Fosfocin